ILB-3132(E12LA6B603)
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →
Components are supplied separately; this is not a premixed LNP. RNA/cargo, buffer and formulation service are not included.
DMA4-H228 is a novel, biodegradable lipidoid specifically engineered for spleen-targeted mRNA delivery. Its structure combines a dimethylamino (DMA4) headgroup with a unique hyperbranched lipid tail (H228) incorporating ester bonds for enhanced biodegradability. This design enables the formation of stable lipid nanoparticles (LNPs) (~170 nm) with high mRNA encapsulation efficiency (>96%). Critically, DMA4-H228 exhibits exceptional intrinsic tropism for the spleen (>98% targeting efficiency after IV administration), requiring no external targeting ligands. It selectively delivers mRNA to splenic antigen-presenting cells (APCs), including dendritic cells, macrophages, and B cells. This triggers potent immune activation: rapid IFNα secretion, upregulation of APC maturation markers (CD86/CD40), and robust antigen-specific immune responses. Demonstrating significant therapeutic potential, DMA4-H228-based mRNA vaccines effectively inhibit tumor growth in melanoma models (e.g., B16F10-OVA). This correlates with increased tumor-infiltrating CD8⁺ T cells, a shift towards pro-inflammatory M1 macrophages, elevated antigen-specific antibodies (IgG), and strong T cell responses (evidenced by IFNγ⁺ spots). Its ability to bypass liver tropism and directly activate splenic APCs makes DMA4-H228 a powerful platform for next-generation mRNA vaccines and cancer immunotherapy.
| CAS No. | Not available |
| Chemical Name | DMA4-H228 |
| Synonyms | DMA4H228, DMA4 H228, |
| SMILES | CCCCCCCCN(CCCCCCCC)C(=O)CCC(=O)OCCOC(=O)CCN(CCC(=O)OCCOC(=O)CCC(=O)N(CCCCCCCC)CCCCCCCC)CCC1CCCN1C |
| Formula | C57H106N4O10 |
| M.Wt | 1007.49 |
| Purity | >95% by ELSD-HPLC |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Dimethylamino-based synthetic lipidoid nanoparticles for selective mRNA delivery to splenic antigen-presenting cells. DOI: 10.1016/j.jconrel.2025.113737 |
| Component | mol% | Role |
|---|---|---|
| DMA4-H228 | 66.67 | Ionizable lipid |
| Cholesterol | 25.67 | Sterol |
| DSPC | 6.67 | Helper phospholipid |
| DMG-PEG2000 | 1 | PEG lipid |
| Reported total | 100.01 | Source values retained |
Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.
| Component | Molecular weight | Molar parts | Normalized mol% | Amount (µmol) | Weight (mg) |
|---|---|---|---|---|---|
| DMA4-H228 | 66.663 | 78.5537 | 79.1420 | ||
| Cholesterol | 25.667 | 30.2456 | 11.6944 | ||
| DSPC | 6.669 | 7.8589 | 6.2097 | ||
| DMG-PEG2000 | 1.000 | 1.1782 | 2.9539 |
Calculated total: 100.0000 mg lipid.
Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.
The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.
Solvent volumes update from the molecular weight above.
| Mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 9.9257 mL | 1.9851 mL | 992.57 μL |
| 25 mg | 24.8141 mL | 4.9628 mL | 2.4814 mL |
| 50 mg | 49.6283 mL | 9.9257 mL | 4.9628 mL |
| 100 mg | 99.2566 mL | 19.8513 mL | 9.9257 mL |
| 250 mg | 248.1414 mL | 49.6283 mL | 24.8141 mL |
Contact our team with the catalog number and requested quantity.